# mTOR-inhibitor treatment of metastatic renal cell carcinoma: contribution of Choi and modified Choi criteria assessed in 2D or 3D to evaluate tumor response

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/mtor-inhibitor-treatment-of-metastatic-renal-cell-carcinoma-contribution-of-choi/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Michele Lamuraglia,Shahm Raslan,Réza‐Thierry Elaidi,Stéphane Oudard,Bernard Escudier,K. Slimane,R. Renard Penna,Mathilde Wagner,Olivier Lucidarme |
| Citations | 14 |
| DOI | 10.1007/s00330-015-3828-7 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W1884611235 |
| PMID | 25953002 |
| Type | article |
| Year | 2015 |

## Paper authors

- [Shahm Raslan](https://scholariq.org/researchers/shahm-raslan/)

## Paper journal

- [European Radiology](https://scholariq.org/journals/european-radiology/)

## Paper primary topic

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)

## Paper topics

- [Renal cell carcinoma treatment](https://scholariq.org/topics/renal-cell-carcinoma-treatment/)
- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [MRI in cancer diagnosis](https://scholariq.org/topics/mri-in-cancer-diagnosis/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.